Clinical trials: Mood Change
Metabolic Complications
Metformin for the Prevention of the Metabolic Side-effects of Zyprexa
We hypothesize that metformin co-administered with olanzapine will be well tolerated and associated with significantly less insulin resistance, weight gain and dyslipidemia as compared to olanzapine plus placebo.
- Trial name
- NCT00682448
- Testing
- Metformin
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Rush University Medical Center
Major Depressive Disorder, Depression
HypErthermia as an Additional Treatment for the Biology and Experience of Depression: Study 2
This randomized two-arm intervention trial administers 8 weekly cognitive behavioral therapy (CBT) sessions and 4 bi-weekly active whole-body hyperthermia (active WBH) sessions or 4 bi-weekly sham WBH sessions to adults aged 18…
- Trial name
- HEATBED2 (NCT05708976)
- Testing
- Cognitive Behavioral Therapy (CBT), Active Whole-Body Hyperthermia (Active WBH)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, San Francisco
Major Depressive Disorder, Soft Tissue Discomfort Syndrome
Functional Change and Efficacy of Duloxetine in Patients With Co-Morbid Depression & Soft Tissue Discomfort Syndrome
The objective of this study is to determine the time course of duloxetine efficacy on the symptoms of Major Depressive Disorder (MDD)and on the symptoms of Soft Tissue Discomfort Syndrome(STDS) via use of 24-hour Actigraph™…
- Conditions
- Major Depressive Disorder, Soft Tissue Discomfort Syndrome, Pain
- Trial name
- NCT01035073
- Testing
- Duloxetine
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Pennsylvania
Depression, Bipolar Disorder
Augmenting Hospitalization for Serious Mental Illness: Cognitive Bias Modification
Approximately 4.1% of the adult US population meets the criteria for SMI, a mental disorder associated with significant functional impairment.
- Conditions
- Depression, Bipolar Disorder, Anxiety Disorders, Psychiatric Disorder
- Trial name
- NCT03509181
- Testing
- I-Change, Symptom Tracking
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Mclean Hospital
Bipolar Disorder
N-Acetyl Cysteine and Aspirin as an Adjunctive Treatment for Bipolar Disorder
We propose to conduct a double-blind placebo-controlled trial with a widely available and prototypical non-steroidal anti-inflammatory agent, aspirin, and an antioxidant agent, NAC, involving symptomatic Bipolar Disorder type I…
- Trial name
- SMRI-Bipolar (NCT01797575)
- Testing
- Aspirin, N-acetyl-cysteine (NAC), Sugar Pill
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- The University of Texas Health Science Center, Houston
Asthma, Rheumatic Disease
Acetaminophen (Tylenol) for Mood and Memory Changes Associated With Corticosteroid Therapy
Studies in humans and animals support that stress and/or elevations in corticosteroids lead to changes in hippocampal structure and functioning.
- Trial name
- NCT00377364
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Texas Southwestern Medical Center
Antipsychotic-induced Weight Gain (AIWG)
A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications
This phase 2, double blind, placebo-controlled, randomized study is to assess the safety, efficacy, and pharmacokinetics (PK) of miricorilant (CORT118335) in obese adults with schizophrenia or bipolar disorder treated with…
- Trial name
- GRATITUDE (NCT03818256)
- Testing
- Miricorilant
- Where
- 27 sites in United States
- Volunteers
- 71 people
- Sponsor
- Corcept Therapeutics
Depression
Behavioral Study of Effects of Low-Level Light Therapy on Mood and Reaction Time
The goal of this project is to use low-level light therapy (LLLT) to enhance neural metabolism in the prefrontal cortex of humans, and measure the effects of LLLT on attentional bias change following a single session of attention…
- Trial name
- NCT02390076
- Testing
- Left Low Level Light Therapy, Attention bias modification, Right Low Level Light Therapy
- Volunteers
- 51 people
- Sponsor
- Seth Disner
Major Depressive Disorder
Supportive and Supportive-Expressive Treatment for Depression
This study will assign patients to two types of psychotherapies in treating people with a major depression disorder, expressive versus supportive techniques, and will examine their ability to benefit from treatment based on their…
- Trial name
- SSETD (NCT02728557)
- Testing
- Supportive-Expressive Therapy, Supportive Therapy
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- University of Haifa
Depression
Brain Energy Metabolism in Individuals With Major Depressive Disorder Receiving Escitalopram
This study will evaluate changes in brain energy metabolism due to treatment with escitalopram in people with major depressive disorder.
- Trial name
- NCT00183677
- Testing
- Escitalopram
- Where
- United States
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
The Relationship Among Changes in Brain Network Activation in Adult Outpatients With Major Depressive Disorder
The purpose of this study is to explore patterns of Brain Network Activation (BNA) changes from baseline to endpoint on 1) efficacy of core symptoms of Major Depressive Disorder (MDD) and 2) improvement of cognitive dysfunction…
- Trial name
- NCT02749721
- Testing
- vortioxetine
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Rush University Medical Center
Hot Flushes, Night Sweats
Progesterone for Perimenopausal Night Sweats
The purpose of this study is to test whether a oral micronized progesterone reduces the Vasomotor Symptom Score comprised of the number and severity of hot flushes and night sweats in perimenopausal women.
- Trial name
- NCT01464697
- Testing
- Oral micronized progesterone
- Where
- Canada
- Volunteers
- 249 people
- Sponsor
- University of British Columbia
Schizophrenia, Schizoaffective Disorder
Estimating and Reducing the Cardiovascular Risk of Patients With Schizophrenia Drugs From Lipid Measures and Ischemic Electrocardiographic Changes
The primary goal of this study is to examine the triglyceride/high-density lipoprotein (TG/HDL) ratio and the ischemic EKG changes in patients with schizophrenia, schizoaffective disorder or bipolar disorder.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- NCT00288353
- Testing
- aripiprazole (Abilify), ziprasidone (Geodon)
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Northwestern University
Attention Deficit Hyperactivity Disorder
Imaging the Effects of Stimulant Medication on Emotional Lability in Patients With ADHD
The aim of this study is to examine the mechanisms by which stimulant medications reduce symptoms in patients with Attention Deficit Hyperactivity Disorder (ADHD).
- Trial name
- NCT01415440
- Testing
- Lisdexamfetamine
- Where
- United States
- Volunteers
- 117 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute
Bipolar Disorder, Medication Adherence
CAE Plus LAI in Individuals With Bipolar Disorder at Risk for Treatment Non-adherence (BD-CAEL)
This is a prospective study using customized adherence enhancement (CAE) and long-acting injectable (LAI) antipsychotic in 30 individuals with bipolar disorder (BD) at risk for treatment non-adherence.
- Conditions
- Bipolar Disorder, Medication Adherence, Medication Non Adherence
- Trial name
- NCT03408873
- Testing
- Abilify Maintena, Customized Adherence Enhancement (CAE)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Martha Sajatovic
Major Depression
Motivational Interviews for Depression in Primary Care
The purpose of the study is to determine whether motivational interviewing with guideline-based medical management for depression will significantly improve time to depression recovery and increase the proportion of subjects in…
- Trial name
- NCT01114334
- Testing
- Guideline-Based Medical Management, Motivational Interviewing for Depression
- Where
- United States
- Volunteers
- 168 people
- Sponsor
- Denver Health and Hospital Authority
Bipolar Disorder, Weight Gain
Topiramate vs. Placebo in Preventing Weight Gain in Bipolar Disorder Treated With Olanzapine
The primary objective of this study is to examine the efficacy of topiramate in combination with olanzapine for the prevention of weight gain in youth with bipolar disorder.
- Trial name
- NCT00394095
- Testing
- Topiramate
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Cincinnati
Schizophrenia, Schizoaffective Disorder
Naltrexone for Antipsychotic-Induced Weight Gain
This study is designed to look at the effects of naltrexone on weight loss in individuals treated with antipsychotic medications.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Bipolar Disorder
- Trial name
- NTX (NCT01866098)
- Testing
- Naltrexone
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- Yale University
Major Depressive Disorder
Augmenting Single-session Behavioral Activation (BA) With Delta-beta Transcranial Alternating Current Stimulation (tACS) for the Treatment of Depression
Investigating whether delta-beta cross-frequency transcranial alternating current stimulation can augment the effects of a single session of behavioral activation in participants with major depressive disorder.
- Trial name
- ABBA (NCT05693922)
- Testing
- Delta-beta cross-frequency transcranial alternating current stimulation via the NeuroConn DC-STIMULATOR MC, Single-session behavioral activation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of North Carolina, Chapel Hill
Covid19, Anosmia
Study of Hesperidin Therapy on COVID-19 Symptoms (HESPERIDIN)
The main aim of this study is to determine the effects of short-term treatment with hesperidin on COVID-19 symptoms in comparison with a placebo.
- Conditions
- Covid19, Anosmia, Fever, Cough
- Trial name
- Hesperidin (NCT04715932)
- Testing
- Hesperidin
- Where
- Canada
- Volunteers
- 216 people
- Sponsor
- Montreal Heart Institute